Exploring Aquestive Therapeutics, Inc. (AQST) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Aquestive Therapeutics (AQST) and what's driving their decisions? Are institutional investors, like Bratton Capital Management, L.P., BlackRock, Inc., and Vanguard Group Inc, with their significant holdings of 48,423,643 shares, shaping the company's direction? Or is it the retail investors, who hold approximately 51.10% of the stock, influencing the market? With key products like Anaphylm potentially revolutionizing anaphylaxis treatment and analysts predicting price targets ranging from $7.00 to $10.00, understanding the investor landscape is more crucial than ever. Dive in to explore the profiles of those investing in AQST and the factors guiding their investment strategies.

Aquestive Therapeutics, Inc. (AQST) Who Invests in Aquestive Therapeutics, Inc. (AQST) and Why?

Understanding the investor profile of Aquestive Therapeutics, Inc. (AQST) provides valuable insights into the market's perception of the company and its future prospects. The ownership structure of AQST is a mix of retail, institutional, and insider holdings.

Key Investor Types

The investor base of Aquestive Therapeutics, Inc. (AQST) can be segmented into the following key types:

• Retail Investors: A significant portion of Aquestive Therapeutics, Inc.'s (AQST) stock is held by retail investors. According to recent data, approximately 51.10% of the company's stock is owned by retail investors. This indicates a substantial interest from individual investors.
• Institutional Investors: Institutions also hold a notable percentage of AQST's shares. Approximately 19.65% of Aquestive Therapeutics, Inc.'s (AQST) stock is held by institutional investors. Major institutional shareholders include:

• Insiders: A portion of the company's shares is held by insiders, comprising about 14.54% of the stock. Douglas Bratton owns the most shares of Aquestive Therapeutics, Inc. (AQST).

Investment Motivations

Several factors attract investors to Aquestive Therapeutics, Inc. (AQST):

• Innovative Technology: Aquestive Therapeutics, Inc. (AQST) specializes in innovative film-based medicines, utilizing its PharmFilm® technology and Adrenaverse platform. These platforms have walls of IP and trade secrets that make it nearly impossible to replicate, and difficult for substitutes to compete against.
• Product Pipeline: The company's pipeline includes products like Libervant™ (diazepam) buccal film for seizures and Anaphylm™ for anaphylaxis, which are expected to drive revenue growth. The FDA's designation of Libervant as a medically superior option is likely to bolster its market acceptance and drive sales.
• Market Position: Aquestive Therapeutics, Inc. (AQST) aims to improve medications and outcomes for patients with central nervous system (CNS) conditions and severe allergies.

Investment Strategies

Investors in Aquestive Therapeutics, Inc. (AQST) may employ various strategies:

• Long-Term Holding: Some institutional investors adopt a long-term holding strategy, as evidenced by the presence of major shareholders like Vanguard Group and BlackRock, Inc.
• Growth Prospects: Analysts predict significant revenue growth for Aquestive Therapeutics, Inc. (AQST), driven by its product pipeline. The company's forecast annual revenue growth rate of 28.29% is expected to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.42%.
• Analyst Ratings: Aquestive Therapeutics, Inc. (AQST) has a consensus rating of 'Buy' from analysts. The average price target is $10.67, with a high forecast of $17.00 and a low forecast of $7.00.

For more information about Aquestive Therapeutics, Inc. (AQST), you can read this comprehensive overview: Aquestive Therapeutics, Inc. (AQST): History, Ownership, Mission, How It Works & Makes Money

Financial Performance: In 2024, Aquestive Therapeutics, Inc.'s (AQST) revenue was $57.56 million, an increase of 13.80% compared to the previous year's $50.58 million. Losses were -$44.14 million, significantly more than in 2023.

Stock Information: As of April 17, 2025, the share price of Aquestive Therapeutics, Inc. (AQST) was $2.51 per share. Analysts have set price targets with a potential upside.

Aquestive Therapeutics, Inc. (AQST) Institutional Ownership and Major Shareholders of Aquestive Therapeutics, Inc. (AQST)

Institutional ownership in Aquestive Therapeutics, Inc. (AQST) provides insights into the stability and investor confidence in the company. Analyzing the top institutional investors, changes in ownership, and the overall impact of these investors can offer a clearer understanding of the stock's potential performance and the company's strategic direction.

Here's an overview of institutional ownership in Aquestive Therapeutics, Inc. (AQST):

• Top Institutional Investors: The largest institutional investors and their corresponding shareholdings in Aquestive Therapeutics, Inc. (AQST) can significantly influence market perception. These major holders often include investment firms, hedge funds, and pension funds.
• Changes in Ownership: Monitoring whether institutional investors have increased or decreased their positions recently is crucial. An increase in holdings may signal positive sentiment, while a decrease could indicate concerns about the company's future prospects.
• Impact of Institutional Investors: Large institutional investors can impact the stock price and overall company strategy. Their actions can drive trading volume and potentially influence corporate decisions.

As of December 31, 2024, the landscape of institutional ownership in Aquestive Therapeutics, Inc. (AQST) is characterized by several key players. According to recent data, the top institutional holders include:

• Vanguard Group Inc: Holding approximately 2,724,518 shares, representing about 8.4% of the company.
• Blackrock Inc: Holding approximately 2,189,179 shares, representing about 6.7% of the company.
• State Street Corp: Holding approximately 740,789 shares, representing about 2.27% of the company.
• Renaissance Technologies LLC: Holding approximately 441,683 shares, representing about 1.35% of the company.
• Geode Capital Management LLC: Holding approximately 357,949 shares, representing about 1.1% of the company.

These major institutional shareholders collectively hold a notable percentage of Aquestive Therapeutics, Inc. (AQST), underscoring the significance of institutional interest in the company. Their investment decisions can reflect their assessment of Aquestive Therapeutics, Inc. (AQST)'s prospects and can influence market dynamics.

Analyzing recent changes in institutional ownership provides valuable insights into the evolving sentiment surrounding Aquestive Therapeutics, Inc. (AQST). For example:

• Vanguard Group Inc: Displayed an increase in shares held by 48,555 shares, marking a change of 1.82% from their previous filing.
• Blackrock Inc: Showed a decrease in shares held by -219,342 shares, marking a change of -9.09% from their previous filing.
• State Street Corp: Increased their holdings by 31,366 shares, reflecting a change of 4.42% from their previous filing.
• Renaissance Technologies LLC: Reduced their position by -156,317 shares, indicating a substantial change of -26.15% from their previous filing.
• Geode Capital Management LLC: Increased their holdings by 14,554 shares, representing a change of 4.24% from their previous filing.

These shifts in ownership can reflect various factors, such as adjustments in portfolio strategy, reassessment of risk, or evolving views on Aquestive Therapeutics, Inc. (AQST)'s growth potential. Monitoring these changes over time can help investors understand the broader trends influencing the stock.

The presence and activities of large institutional investors can exert considerable influence on Aquestive Therapeutics, Inc. (AQST)'s stock price and strategic options. Their substantial holdings can lead to:

• Price Stability: Significant institutional ownership can reduce volatility by providing a stable base of long-term investors.
• Market Confidence: The presence of reputable institutions can enhance investor confidence, attracting additional investment.
• Corporate Governance: Institutional investors often engage with company management, influencing corporate governance and strategic direction.

For a deeper dive into the company's financial standing, check out: Breaking Down Aquestive Therapeutics, Inc. (AQST) Financial Health: Key Insights for Investors

Below is a detailed table presenting the major shareholders in Aquestive Therapeutics, Inc. (AQST) as of 2024:

Understanding the dynamics of institutional ownership in Aquestive Therapeutics, Inc. (AQST) is essential for investors seeking to make informed decisions. By tracking the actions of major shareholders and analyzing changes in ownership, investors can gain valuable insights into the company's potential and market sentiment.

Aquestive Therapeutics, Inc. (AQST) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Aquestive Therapeutics, Inc. (AQST) provides critical insights into the company's stability, strategic direction, and potential for growth. Key investors can significantly influence company decisions and stock performance through their holdings and actions.

While specific, real-time data on all investors and their recent moves fluctuates, here's a general overview based on the latest available information and typical investor influence patterns:

• Institutional Investors: These entities, such as mutual funds, hedge funds, and pension funds, often hold substantial shares in Aquestive Therapeutics, Inc. (AQST). Their investment decisions are driven by in-depth financial analysis and can significantly impact the stock price. Notable institutional investors may include:
  • Vanguard Group: Known for its large index funds and long-term investment strategies.
  • BlackRock Fund Advisors: Another major asset manager with diverse holdings.
  • State Street Corp: A significant player in the investment management space.

These institutional investors' influence stems from their large holdings, which allow them to vote on key company matters and potentially influence strategic decisions. Recent moves, such as increasing or decreasing their positions, are closely watched by other investors as signals of confidence or concern about the company's prospects.

• Activist Investors: While not always present, activist investors can take significant stakes in a company and push for changes in management, strategy, or operations to increase shareholder value. Their involvement can lead to substantial stock movements and shifts in company direction.

• Individual Investors: A large base of retail investors also holds shares in Aquestive Therapeutics, Inc. (AQST). While their individual holdings may be smaller, their collective actions can still influence the stock price, particularly in times of high trading volume or market volatility.

To gain a deeper understanding of Aquestive Therapeutics, Inc. (AQST), explore its history, mission, ownership structure, and revenue generation methods: Aquestive Therapeutics, Inc. (AQST): History, Ownership, Mission, How It Works & Makes Money

Aquestive Therapeutics, Inc. (AQST) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for assessing the potential of Aquestive Therapeutics, Inc. (AQST). Recent market dynamics and analyst perspectives provide valuable insights into the company's trajectory.

Aquestive Therapeutics, Inc. (AQST) serves as a case study for how shifts in ownership and investor sentiment can influence stock performance and corporate strategy. Examining these dynamics provides a clearer understanding of the factors driving Aquestive Therapeutics, Inc.'s (AQST) market behavior.

Recent ownership trends can significantly influence a company's stock performance. Major shifts in investor holdings often trigger market reactions, reflecting a reassessment of the company’s prospects. Keeping an eye on these changes helps in understanding the evolving sentiment around Aquestive Therapeutics, Inc. (AQST).

Here’s a look at factors influencing investor sentiment:

• Major Shareholder Sentiment: The prevailing sentiment of major shareholders—whether positive, neutral, or negative—can significantly sway market confidence.
• Market Reactions: How the stock market responds to changes in ownership or large investor moves provides immediate feedback on the perceived health and prospects of Aquestive Therapeutics, Inc. (AQST).
• Analyst Perspectives: Insights from analysts on the impact of key investors offer professional assessments of Aquestive Therapeutics, Inc.'s (AQST) future.

For example, significant stock acquisitions by institutional investors are generally seen as a positive signal, potentially driving up the stock price. Conversely, large sell-offs might indicate concerns about the company's future, leading to a price decline.

Analyst ratings and price targets are also crucial indicators. Upgrades from analysts often reflect increased confidence in Aquestive Therapeutics, Inc.'s (AQST), while downgrades may signal underlying issues. Monitoring these perspectives helps investors gauge the overall sentiment and potential risks.

News sentiment analysis offers another layer of insight. Natural language processing algorithms scan news articles and social media to gauge the overall tone surrounding Aquestive Therapeutics, Inc. (AQST). Positive news coverage tends to boost investor confidence, whereas negative coverage can dampen it.

Several factors can drive investor sentiment regarding Aquestive Therapeutics, Inc. (AQST):

• Financial Performance: Revenue growth, profitability, and cash flow are critical metrics.
• Pipeline Developments: Progress in clinical trials and regulatory approvals for new drugs can significantly impact investor confidence.
• Market Conditions: Broader economic trends and industry-specific factors also play a role.

Keeping a close watch on these elements helps investors stay informed and make well-considered decisions regarding Aquestive Therapeutics, Inc. (AQST).

Here is a hypothetical example of how different investor activities and market reactions might play out:

These scenarios illustrate how interconnected investor actions, market responses, and analyst evaluations are in shaping the perception and valuation of Aquestive Therapeutics, Inc. (AQST).

To gain more insights into Aquestive Therapeutics, Inc.'s (AQST) financial standing, consider exploring: Breaking Down Aquestive Therapeutics, Inc. (AQST) Financial Health: Key Insights for Investors.